Search
Results for "antiviral"
-
ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen
Media
First published: 10 July 2019
Week 48 results from the TANGO study will be presented this month at 10th International AIDS Society Conference on HIV Science (IAS 2019).
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-phase-iii-study-meets-primary-endpoint/
-
ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection
Media
First published: 24 July 2019
Data from the TANGO study presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) demonstrate non-inferior efficacy of Dovato▼ (dolutegravir/lamivudine) in virally sup...
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-week-48-results-in-first-study-to-evaluate-treatment-switch-from-taf-containing-regimen/
-
ViiV Healthcare Announces CHMP positive opinion to lower the age and weight limit for Tivicay® (dolutegravir) in children and adolescents living with HIV in Europe
Media
First published: 16 December 2016
The CHMP has adopted a positive opinion to reduce the weight and age limit for the treatment of HIV with Tivicay.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-chmp-positive-opinion-to-lower-the-age-and-weight-limit-for-tivicay-dolutegravir-in-children-and-adolescents-living-with-hiv-in-europe/
-
ViiV Healthcare receives EU marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV
Media
First published: 03 September 2014
ViiV Healthcare announced today that the European Commission (EC) has granted marketing authorisation for Triumeq® (dolutegravir 50mg / abacavir 600mg / lamivudine 300mg) tablets for the treatment ...
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-triumeq-dolutegravirabacavirlamivudine-a-new-once-daily-single-pill-regimen-for-the-treatment-of-hiv/
-
ViiV Healthcare presents data from Phase III study of dolutegravir vs raltegravir in treatment-experienced adults with HIV-1
Media
First published: 06 March 2013
ViiV Healthcare presents 24-week interim results from Phase III SAILING study at the 20th Conference on Retroviruses and Opportunistic Infections (CROI)
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-data-from-phase-iii-study-of-dolutegravir-vs-raltegravir-in-treatment-experienced-adults-with-hiv-1/
-
Shionogi-ViiV Healthcare announces completion of initial clinical registration package for dolutegravir in HIV
Media
First published: 04 October 2012
Shionogi-ViiV Healthcare LLC today announced that the phase III data required for initial regulatory filings of the investigational integrase inhibitor dolutegravir in adults infected with HIV are ...
https://www.gsk.com/en-gb/media/press-releases/shionogi-viiv-healthcare-announces-completion-of-initial-clinical-registration-package-for-dolutegravir-in-hiv/
-
GSK and Enigma Diagnostics announce commercial partnership to develop point-of-care influenza diagnostics
Media
First published: 20 July 2009
GlaxoSmithKline (GSK) and Enigma Diagnostics Limited today announced that they have signed worldwide agreements to develop and supply the first point-of-care diagnostic influenza tests to identify ...
https://www.gsk.com/en-gb/media/press-releases/gsk-and-enigma-diagnostics-announce-commercial-partnership-to-develop-point-of-care-influenza-diagnostics/
-
GSK and Concert Pharmaceuticals form alliance to develop novel deuterium-modified drugs
Media
First published: 01 June 2009
GlaxoSmithKline (NYSE: GSK) and Concert Pharmaceuticals announced today that they will collaborate to develop and commercialise deuterium-containing medicines. The deal includes three of Concert...
https://www.gsk.com/en-gb/media/press-releases/gsk-and-concert-pharmaceuticals-form-alliance-to-develop-novel-deuterium-modified-drugs/
-
GlaxoSmithKline update: influenza A (H1N1)
Media
First published: 30 April 2009
GlaxoSmithKline (GSK) is committed to supporting governments and health authorities around the world to respond to the emergence of the new influenza A (H1N1) strain.
https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-influenza-a-h1n1/
-
Phase II study results showed comparable viral suppression rates at 96 weeks for a two-drug regimen of long-acting cabotegravir and rilpivirine and a three-drug regimen in patients with HIV
Media
First published: 24 July 2017
LATTE-2 study results published in The Lancet and presented at International AIDS Society Meeting
https://www.gsk.com/en-gb/media/press-releases/phase-ii-study-results-showed-comparable-viral-suppression-rates-at-96-weeks/